{"id":"NCT01950299","sponsor":"Virginia Commonwealth University","briefTitle":"Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)","officialTitle":"Interleukin-1 Blockade With Anakinra in Patients With ST-segment Elevation Myocardial Infarction - the Virginia Commonwealth University Anakinra Remodeling Trial 3","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2014-07-01","primaryCompletion":"2018-12-23","completion":"2018-12-23","firstPosted":"2013-09-25","resultsPosted":"2019-12-18","lastUpdate":"2019-12-18"},"enrollment":99,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Acute Myocardial Infarction"],"interventions":[{"type":"DRUG","name":"Anakinra 100 mg","otherNames":["Kineret"]},{"type":"DRUG","name":"Anakinra 100 mg","otherNames":["Kineret"]},{"type":"DRUG","name":"Placebo","otherNames":["Placebo injections twice daily"]}],"arms":[{"label":"Anakinra (standard dose)","type":"EXPERIMENTAL"},{"label":"Anakinra (high dose)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"VCU-ART3 is a double-blind randomized clinical trial of anakinra high dose vs anakinra standard dose vs placebo in patients with ST-segment elevation myocardial infarction (STEMI) measuring the effects on the acute rise and fall of the plasma C reactive protein levels during the first 14 days.","primaryOutcome":{"measure":"Acute Phase Response (CRP Levels)","timeFrame":"14 days","effectByArm":[{"arm":"Anakinra (Standard Dose)","deltaMin":60.03,"sd":null},{"arm":"Anakinra (High Dose)","deltaMin":86.35,"sd":null},{"arm":"Placebo","deltaMin":213.75,"sd":null}],"pValues":[]},"eligibility":{"minAge":"21 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":2,"countries":["United States"]},"refs":{"pmids":["32648087","32122219","30033595"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":33},"commonTop":["Injection Site Reaction"]}}